Immunohistochemical investigation of cell cycle and apoptosis regulators (Survivin, β-Catenin, P53, Caspase 3) in canine appendicular osteosarcoma

BMC Veterinary Research

Volumn 8, Issue , 2012, Pages

  Bongiovanni, Laura ^a   Mazzocchetti, Francesca ^a   Malatesta, Daniela ^a   Romanucci, Mariarita ^a   Ciccarelli, Andrea ^a   Buracco, Paolo ^b   De Maria, Raffaella ^b   Palmieri, Chiara ^a   Martano, Marina ^b   Morello, Emanuela ^b   Maniscalco, Lorella ^b   Salda, Leonardo D ^a  

^a UNIVERSITY OF TERAMO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE 3; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN P53;

ANIMAL; ANIMAL DISEASE; ARTICLE; CELL CYCLE; DOG; DOG DISEASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LIMB; MALE; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BETA CATENIN; CASPASE 3; CELL CYCLE; DOG DISEASES; DOGS; EXTREMITIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; OSTEOSARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861983607     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-8-78     Document Type: Article

References (81)

1. Endicott M. Principles of treatment for osteosarcoma. Clin Tech Small Anim Pract 2003, 18:110-114. 10.1053/svms.2003.36626, 12831072.
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009, 115(7):1531-1543. 10.1002/cncr.24121, 2813207, 19197972.
3. Mueller F, Fuchs B, Kaser-Hotz B. Comparative Biology of Human and Canine Osteosarcoma. Anticancer Res 2007, 27:155-164.
4. De Maria R, Miretti S, Iussich S, Olivero M, Morello E, Bertotti A, Christensen JG, Levine RA, Buracco P, Di Renzo MF. Met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma. J Pathol 2009, 218:399-408. 10.1002/path.2549, 19402129.
5. Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA. Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 2009, 9:81. 10.1186/1471-2407-9-81, 2666757, 19284568.
6. Thomas R, Wang HJ, Tsai PC, Langford CF, Fosmire SP, Jubala CM, Getzy DM, Cutter GR, Modiano JF, Breen M. Influence of genetic background on tumor karyotypes: evidence for breed-asscoiated aberrations in canine appendicular osteosarcoma. Chromosome Res 2009, 17:365-377. 10.1007/s10577-009-9028-z, 19337847.
7. Morello E, Martano M, Buracco P. Biology, diagnosis and treatment of canine appendicular osteosarcoma: Similarities and differences with human osteosarcoma. Vet J 2011, 189(3):268-277. 10.1016/j.tvjl.2010.08.014, 20889358.
8. Withrow SJ, Wilkins RM. Cross talk from pets to people: translational osteosarcoma treatments. ILAR J 2010, 51(3):208-213.
9. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, Wilson M, Radinsky R. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004, 92(1):77-91. 10.1002/jcb.20046, 15095405.
10. Flint AF, U'Ren L, Legare ME, Withrow SJ, Dernell W, Hanneman WH. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Vet Pathol 2004, 41(3):291-296. 10.1354/vp.41-3-291, 15133183.
11. Mullins MN, Lana SE, Dernell WS, Ogilvie GK, Withrow SJ, Ehrhart EJ. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med 2004, 18(6):859-865. 10.1111/j.1939-1676.2004.tb02633.x, 15638270.
12. Kow K, Thamm DH, Terry J, Grunerud K, Bailey SM, Withrow SJ, Lana SE. Impact of telomerase status on canine osteosarcoma patients. J Vet Intern Med 2008, 22(6):1366-1372. 10.1111/j.1939-1676.2008.0175.x, 18761602.
13. Kirpensteijn J, Kik M, Teske E, Rutteman GR. TP53 gene mutations in canine osteosarcoma. Vet Surg 2008, 37(5):454-460. 10.1111/j.1532-950X.2008.00407.x, 18986312.
14. Selvarajah GT, Kirpensteijn J, van Wolferen ME, Rao NA, Fieten H, Mol JA. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer 2009, 8:72. 10.1186/1476-4598-8-72, 2746177, 19735553.
15. Selvarajah GT, Kirpensteijn J. Prognostic and predictive biomarkers of canine osteosarcoma. Vet J 2010, 185(1):28-35. 10.1016/j.tvjl.2010.04.010, 20493743.
16. O'Donoghue LE, Ptitsyn AA, Kamstock DA, Siebert J, Thomas RS, Duval DL. Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome. BMC Cancer 2010, 10:506. 10.1186/1471-2407-10-506, 2955038, 20860831.
17. Sharili AS, Allen S, Smith K, Hargreaves J, Price J, McGonnell I. Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy. Tumour Biol 2011, 32(3):515-526. 10.1007/s13277-010-0146-1, 3109975, 21207222.
18. Romanucci M, D'Amato G, Malatesta D, Bongiovanni L, Palmieri C, Ciccarelli A, Buracco P, Morello E, Maniscalco L, De Maria R, Martano M, Della Salda L. Heat shock protein expression in canine osteosarcoma. Cell Stress Chaperones 2012, 17(1)):131-138. 3227845, 22015573.
19. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, Peabody T, Simon MA, Montag AG, He TC. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002, 102(4):338-342. 10.1002/ijc.10719, 12402302.
20. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukay K. Cytoplasmatic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 2003, 20:525-529. 10.1023/A:1025821229013, 14598886.
21. Kashima T, Kawaguchi J, Takeshita S, Kuroda M, Takanashi M, Horiuchi H, Imamura T, Ishikawa Y, Ishida T, Mori S, Machinami R, Kudo A. Anomalous cadherin expression in osteosarcoma, Possible relationships to metastasis and morphogenesis. Am J Pathol 1999, 155(5):1549-1555. 10.1016/S0002-9440(10)65471-5, 1866957, 10550312.
22. Kashima T, Nakamura K, Kawaguchi J, Takanashi M, Ishida T, Aburatani H, Kudo A, Fukayama M, Grigoriadis AE. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 2003, 104:147-154. 10.1002/ijc.10931, 12569568.
23. Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, Toretsky JA, Uren A. Wnt 10 b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 2008, 51:349-355. 10.1002/pbc.21595, 18465804.
24. Clenton-Jansen AM, Anninga JK, Briaire-de Bruijn IH, Romeo S, Oosting J, Egeler RM, Gelderblom H, Taminiau AH, Hogendoorn PC. Profiling 78 of high grade central osteosarcoma and its putative progenitor cells identifies tumorigenic pathways. Br J Cancer 2009, 101:1909-1918. 10.1038/sj.bjc.6605405, 2788255, 19888226.
25. Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL. Antitumor activity of natural compounds, curcumin and PKF 118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Invest New Drugs 2010, 28(6):766-782. 10.1007/s10637-009-9311-z, 19730790.
26. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol 2010, 220(1):24-33. 10.1002/path.2628, 19882675.
27. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza B, Yang R, Huvos AG, Meyers PA, Gorlick R. Expression of LDL-receptors-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004, 109:106-111. 10.1002/ijc.11677, 14735475.
28. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas MD. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted distruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009, 119:837-851. 10.1172/JCI37175, 2662557, 19307728.
29. Zhang F, Chen A, Chen J, Yu T, Guo F. Influence of β-catenin small interfering RNA on human osteosarcoma cells. J Huazhong Univ Sci Technolog Med Sci 2011, 31(3):353-358. 10.1007/s11596-011-0380-9, 21671177.
30. Trieb K, Lehner R, Stulnig R, Sulzbacher I, Shoryer KR. Survivin expression in human osteosarcoma is amarker for survivalEur. J Surg Oncol 2003, 29:379-382.
31. Wang W, Huiying L, Wang A. Expression of Survivin and correlation with PCNA in Osteosarcoma. J Surg Oncol 2006, 93:578-584. 10.1002/jso.20507, 16705726.
32. Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J. Survivin as a prognostic factor for osteosarcoma patients. JSHC 2006, 39(3):95-100.
33. Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J. Survivin expression levels as Indipendent predictors of survival for osteosarcoma patients. J Orthop Res 2007, 25(1):116-121. 10.1002/jor.20291, 17034065.
34. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008, 134(3):281-297. 10.1007/s00432-007-0330-x, 17965883.
35. Do SI, Jung WW, Kim HS, Park Y. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Inter Journal of oncol 2009, 34:797-803.
36. Shoeneman JK, Ehrhart EJ, Eickhoff JC, Charles JB, Powers BE, Thamm DH. Expression and function of survivin in canine osteosarcoma. Cancer Res 2012, 72(1)):249-259.
37. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011, 16(11-12):485-494.
38. Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 2009, 8(17):2708-2710. 10.4161/cc.8.17.9457, 2819076, 19717980.
39. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362(9379):205-209. 10.1016/S0140-6736(03)13910-4, 12885482.
40. Bongiovanni L, Muller EJ, Della Salda L. Survivin in skin pathologies. Exp Dermatol 2011, 20(6):456-463.
41. Mendoza S, Conischi T, Dernell WS, Withrow SJ, Miller CW. Status of the p53, Rb and Mdm2 Genes in Canine Osteosarcoma. Anticancer Res 1998, 18:4449-4454.
42. Chandar N, Saluja R, Lamar PC, Kolman K, Prozialeck WC. P53 and Beta-catenin activity during estrogen treatment of osteoblasts. Cancer Cell International 2005, 5:24. 10.1186/1475-2867-5-24, 1192811, 16053526.
43. Damalas A, Kahan S, Shtutman M, Ben-Ze'ev A, Oren M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperated with Ras in transformation. EMBO J 2001, 20(17):4912-4922. 10.1093/emboj/20.17.4912, 125598, 11532955.
44. Slayter MV, Boosinger TR, Pool RR, Dammrich K, Misdorp W, Larsen S. Histological classification of bone and joint tumors of domestic animals, Vol.1 1994, 5-45. Armed Forces Institute of Pathology, Washington DC, 2.
45. Kirpensteijn J, Kik M, Rutteman GR, Teske E. Prognostic significance of a new histologic grading system for Canine Osteosarcoma. Vet Pathol 2002, 39(2):240-246. 10.1354/vp.39-2-240, 12009062.
46. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8(5):739-750. 10.1016/j.devcel.2005.03.016, 15866164.
47. Glass DA, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology 2007, 148(6):2630-2634. 10.1210/en.2006-1372, 17395705.
48. Thomas DM. Wnts, bone and cancer. J Pathol 2010, 220(1):1-4. 10.1002/path.2635, 19890890.
49. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127(3):469-480. 10.1016/j.cell.2006.10.018, 17081971.
50. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007, 19(2):150-158. 10.1016/j.ceb.2007.02.007, 17306971.
51. Stein TJ, Holmes KE, Muthuswamy A, Thompson V, Huelsmeyer MK. Characterization of β-catenin expression in canine osteosarcoma. Vet Comp Oncol 2011, 9(1):65-73. 10.1111/j.1476-5829.2010.00236.x, 3099435, 21303455.
52. Piskun CM, Muthuswamy A, Huelsmeyer MK, Thompson V, Stein TJ. Wnt/β-catenin expression does not correlate with serum alkaline phosphatase concentration in canine osteosarcoma patients. PLoS One 2011, 6(10):e26106. 10.1371/journal.pone.0026106, 3191167, 22022527.
53. Garzotto CK, Berg J, Hoffmann WE, Rand WM. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Int Med 2000, 14:587-592.
54. Behrens J, Lustig B. The Wnt connection to tumorigenesis. Int J Dev Biol 2004, 48:477-487. 10.1387/ijdb.041815jb, 15349822.
55. Verkaar F, van der Stelt M, Blankesteijn WM, van der Doelen AA, Zaman GJ. Discovery of novel small molecule activators of β-catenin signaling. PLoS One 2011, 6(4):e19185. 10.1371/journal.pone.0019185, 3084789, 21559429.
56. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007, 67(13):5999-6002. 10.1158/0008-5472.CAN-07-0494, 17616652.
57. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005, 4:11. 10.1186/1476-4598-4-11, 554981, 15743529.
58. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999, 59:6097-6102.
59. Su L, Wang Y, Xiao M, Lin Y, Yu L. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 110(4):484-491. 10.1016/j.tripleo.2010.04.009, 20868995.
60. Lechler P, Renkawitz T, Campean V, Balakrishnan S, Tingart M, Grifka J, Schaumburger J. The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer 2011, 11:120. 10.1186/1471-2407-11-120, 3076263, 21457573.
61. Cheung CH, Cheng L, Chang KY, Chen HH, Chang JY. Investigations of survivin: the past, present and future. Front Biosci 2011, 16:952-961. 10.2741/3728, 21196211.
62. Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011, 11:125. 10.1186/1471-2407-11-125, 3079692, 21481226.
63. McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 2009, 125(12):2792-2801. 10.1002/ijc.24660, 19544563.
64. Van Leeuwen IS, Cornelisse CJ, Misdorp W, Goedegebuure SA, Kirpensteijn J, Rutteman GR. p53 gene mutations in osteosarcoma in the dog. Cancer Lett 1997, 111:173-178. 10.1016/S0304-3835(96)04529-6, 9022143.
65. Johnson AS, Couto CG, Weghorst CM. Mutations of p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis 1998, 19:213-217. 10.1093/carcin/19.1.213, 9472714.
66. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 1990, 50(24):7950-7954.
67. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma and stem cell Differentiation. Clin Orthop Relat Res 2008, 466:2114-2130. 10.1007/s11999-008-0335-z, 2492997, 18563507.
68. Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Werner B, Roessner A. Analysis of mutant p53 protein in osteosarcomas and other malignant and beign lesions of bone. J Cancer Res Clin Oncol 1993, 119:172-178. 10.1007/BF01229533, 8418091.
69. Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med 2010, 150(2):237-242. 10.1007/s10517-010-1114-x, 21240382.
70. Sagartz JE, Bodley WL, Gamblin RM, Couto CG, Tierney LA, Capen CC. p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Vet Pathol 1996, 33:213-221. 10.1177/030098589603300211, 8801715.
71. Loukopoulos P, Thornthon JR, Robison WF. Clinical and Pathologic Relevance of p53 Index in canine osseus tumors. Vet Pathol 2003, 40:237-248. 10.1354/vp.40-3-237, 12724563.
72. Altieri DC. New wirings in the survivin networks. Oncogene 2008, 27(48):6276-6284. 10.1038/onc.2008.303, 2683067, 18931693.
73. Buracco P, Martano M, Morello E, Vasconi ME. Pasteurized tumoral autograft as a novel procedure of limb sparing in dogs: a clinical report in a canine distal radial osteosarcoma. Vet Surg 2002, 31(6):525-532. 10.1053/jvet.2002.34674, 12415521.
74. Morello E, Vasconi E, Martano M, Peirone B, Buracco P. Pasteurized Tumoral Autograft and Adjuvant Chemotherapy for the Treatment of Canine Distal Radial Osteosarcoma: 13 cases. Vet Surg 2003, 32(6):539-544. 10.1111/j.1532-950X.2003.00539.x, 14648532.
75. Dernell WS, Ehrhart NP, Straw RC, Vail DM. Tumors of the skeletal system. Withrow & MacEwen's Small animal clinical oncology 2007, 540-582. Elsevier, St Louis, Missouri, Withrow SJ, Vail DM, Saunders , 4.
76. Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, LaRue SM, Ogilvie GK, Vail DM, Morrison WB, McGee M, Dickinson. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991, 5:205-210. 10.1111/j.1939-1676.1991.tb00950.x, 1941754.
77. Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995, 206:1555-1560.
78. Chun R, Garrett LD, Henry C, Wall M, Smith A, Azene NM. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc 2005, 41:382-387.
79. Bongiovanni L, Colombi I, Fortunato C, Della Salda L. Survivin expression in canine epidermis and in canine and human cutaneous squamous cell carcinomas. Vet Dermatol 2009, 20(5-6):369-376.
80. Bongiovanni L, Malatesta D, Brachelente C, D'Egidio S, Della Salda L. β-Catenin In Canine Skin: Immunohistochemical Pattern Of Expression In Normal Skin And Cutaneous Epithelial Tumors. J Comp Pathol 2011, 145(2-3):138-147.
81. Bongiovanni L, Romanucci M, Fant P, Lagadic M, Della Salda L. Apoptosis and anti-apoptotic heat shock proteins in canine cutaneous infundibular keratinizing acanthomas and squamous cell carcinomas. Vet Dermatol 2008, 19(5):271-279. 10.1111/j.1365-3164.2008.00687.x, 18803621.